Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)

The aim of this study was to assess the efficacy and safety of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as second- or third-line treatment for elderly Japanese patients with non-small-cell lung cancer (NSCLC). The patients eligible for this phase II tria...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Mol Clin Oncol
Glavni autori: Miyawaki, Masayoshi, Naoki, Katsuhiko, Yoda, Satoshi, Nakayama, Sohei, Satomi, Ryosuke, Sato, Takashi, Ikemura, Shinnosuke, Ohgino, Keiko, Ishioka, Kota, Arai, Daisuke, Namkoong, Ho, Otsuka, Kengo, Miyazaki, Masaki, Tani, Tetsuo, Kuroda, Aoi, Nishino, Makoto, Yasuda, Hiroyuki, Kawada, Ichiro, Koh, Hidefumi, Nakamura, Morio, Terashima, Takeshi, Sakamaki, Fumio, Sayama, Koichi, Betsuyaku, Tomoko, Soejima, Kenzo
Format: Artigo
Jezik:Inglês
Izdano: D.A. Spandidos 2017
Teme:
Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5403701/
https://ncbi.nlm.nih.gov/pubmed/28451422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2017.1154
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items